Ophthalmology · GlaucomaRegulatory Approvalregulatorymid-term

Amneal's ANDA217288 for Brimonidine Tartrate and Timolol Maleate Receives AP Status

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/9/2026, 12:34:09 PM

Assessment confidence: 43% · The main uncertainty is whether medium-relevance evidence fully captures sub-indication-specific dynamics.

Executive Thesis

The FDA's grant of Abbreviated Approval status to Amneal's ANDA217288 for Brimonidine Tartrate and Timolol Maleate is significant as it positions Amneal competitively within the glaucoma treatment market. This development necessitates a review of market strategies by other players in the ophthalmic sector to maintain their market share. Regulatory context from FDA (FDA AP — BRIMONIDINE TARTRATE AND TIMOLOL MALEATE (SUPPL)) supports the near-term read. Assessment grounded in 11 ranked evidence items (0 high-relevance).

Strategic Assessment

Portfolio teams should assess the implications of this approval on market share and pricing strategies for glaucoma treatments. The strongest clinical anchor is Ondexxya for Intravenous Injection 200mg Drug Use Result Investigation (All Case Investigation) (ClinicalTrials.gov), sponsor/company relevance (astrazeneca). In ophthalmology, 8 regulatory and 2 competitive items passed relevance filtering for Amneal.

Competitive Pressure

The most relevant competitive pressure comes from Roche's Elecsys IGRA TB Test Receives CE Mark for Tuberculosis Detection (Humanexa Signals) — mechanism alignment (io ); sponsor/company relevance (roche). Secondary pressure from Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis. This approval may enhance Amneal's position in the ophthalmic market, particularly in the glaucoma segment, potentially impacting competitors with similar formulations.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — BRIMONIDINE TARTRATE AND TIMOLOL MALEATE (SUPPL) (FDA). Entity match (amneal); Regulatory pathway relevance (nda). The Abbreviated Approval status indicates a streamlined pathway for Amneal, which may influence the regulatory strategies of other companies with similar products seeking approval.

Key Risks

Elevated medium regulatory exposure for Amneal could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Amneal's entry with an approved product could lead to price competition and market share shifts in the glaucoma segment, affecting revenue projections for existing competitors.
Portfolio teams should assess the implications of this approval on market share and pricing strategies for glaucoma treatments.

What Would Change This Assessment

This becomes more urgent if Monitor for the final approval and market launch timeline for ANDA217288, as well as competitor responses.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — BRIMONIDINE TARTRATE AND TIMOLOL MALEATE (SUPPL)
FDAmedium relevance
Entity match (amneal); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BRIMONIDINE TARTRATE AND TIMOLOL MALEATE (ORIG)
FDAmedium relevance
Entity match (brimonidine tartrate); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BRIMONIDINE TARTRATE AND TIMOLOL MALEATE (ORIG)
FDAmedium relevance
Entity match (brimonidine tartrate); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BRIMONIDINE TARTRATE AND TIMOLOL MALEATE (SUPPL)
FDAmedium relevance
Entity match (brimonidine tartrate); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BRIMONIDINE TARTRATE (SUPPL)
FDAmedium relevance
Entity match (brimonidine tartrate); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BRIMONIDINE TARTRATE (SUPPL)
FDAmedium relevance
Entity match (brimonidine tartrate); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BRIMONIDINE TARTRATE (ORIG)
FDAmedium relevance
Entity match (brimonidine tartrate); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BRIMONIDINE TARTRATE (ORIG)
FDAmedium relevance
Entity match (brimonidine tartrate); Regulatory pathway relevance (nda)
FDA document
View source

Ondexxya for Intravenous Injection 200mg Drug Use Result Investigation (All Case Investigation)
ClinicalTrials.govlow relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
VertiGreens Investigating the Effects of Iron Biofortification of Microgreens on Iron Status in Women
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Trial of Treatments for COVID-19 in Hospitalized Adults
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Remote Dynamic Cycling for the Customized Off-site Rehab in Parkinson's Disease
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Roche's Elecsys IGRA TB Test Receives CE Mark for Tuberculosis Detection
Humanexa Signalsmedium relevance
Mechanism alignment (IO ); Sponsor/company relevance (Roche)
Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochelow relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochelow relevance
Sponsor/company relevance (Roche)
FDA document
View source
Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
Novartislow relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Sandoz Receives FDA Approval for Liraglutide ANDA212972
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities
FDA Approves Veklury as First Treatment for COVID-19
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Baseline microperimetry and metabolic status predict functional outcomes in diabetic macular oedema: a prospective cohort study of anti-VEGF therapy.
PubMedmedium relevance
Sub-indication match (ophthalmology)
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
RNA polymerase II phosphorylation dynamics: from molecular mechanisms to human disease.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
The role of RNA modifications in cancer translational control.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Amneal
Brimonidine Tartrate
Timolol Maleate

Commercial impact

medium

Amneal's entry with an approved product could lead to price competition and market share shifts in the glaucoma segment, affecting revenue projections for existing competitors.

Regulatory impact

medium

The Abbreviated Approval status indicates a streamlined pathway for Amneal, which may influence the regulatory strategies of other companies with similar products seeking approval.

What to watch

Monitor for the final approval and market launch timeline for ANDA217288, as well as competitor responses.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.